Clinical Trials on Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents in New Zealand

Total 3 results

Takeda

Completed

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents

United States
Luye Pharma Group Ltd.

Completed

Relative Bioavailability of LY03010 Compared to Listed Drug

Mental Disorders | Psychotic Disorders | Mood Disorders | Schizophrenia | Molecular Mechanisms of Pharmacological Action | Tranquilizing Agents | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents | Central Nervous System Depressants | Neurotransmitter Agents | Schizophrenia Spectrum

United States
Maimonides Medical Center

Recruiting

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

Aggression | Behavioral Symptoms | Pathologic Processes | Nervous System Diseases | Obesity | Neurologic Manifestations | Neurobehavioral Manifestations | Congenital Abnormalities | Overnutrition | Nutrition Disorders | Genetic Diseases, Inborn | Intellectual Disability | Self-Injurious Behavior | Abnormalities, Multiple and other conditions

United States

3

Subscribe